Scot Richard Mente
Pfizer
43 Papers
194 Citations
Scot Richard Mente is an academic researcher from Pfizer. The author has contributed to research in topics: Casein kinase 1 & Chemistry. The author has an hindex of 17, co-authored 41 publications. Previous affiliations of Scot Richard Mente include Pennsylvania State University.
Chat about Author
Papers
Solvation and the Excited-State Tautomerization of 7-Azaindole and 1-Azacarbazole: Computer Simulations in Water and Alcohol Solvents
TL;DR: In this paper, computer simulations are performed in order to investigate the role of hydroxylic solvents in catalyzing the excited-state tautomerization of 7-azaindole (7-AI) and 1-azacarbazole (1-AC).
129
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
Allen J. Duplantier,Stacey L. Becker,Michael John Bohanon,Kris A. Borzilleri,Boris A. Chrunyk,James T. Downs,Lain-Yen Hu,Ayman El-Kattan,Larry C. James,Shenping Liu,Jiemin Lu,Noha Maklad,Mahmoud N. Mansour,Scot Richard Mente,Mary Piotrowski,Subas M. Sakya,Sheehan Susan M,Stefanus J. Steyn,Christine A. Strick,Victoria A. Williams,Lei Zhang +20 more
TL;DR: Subsequent evaluation against the rat DAAO enzyme revealed a divergent SAR versus the human enzyme and may explain the high exposures of drug necessary to achieve significant changes in rat or mouse cerebellum D-serine.
118
Computer simulations of the solvatochromism of betaine-30
TL;DR: In this paper, Monte Carlo simulations of the pyridinium N-phenolate dye "Betaine-30" in 12 solvents (20 solvent representations) were performed in order to explore the molecular basis of the ET(30) scale of solvent polarity.
100
Discovery of two clinical histamine H(3) receptor antagonists: trans-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and trans-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-N-(2-methylpropyl)cyclobutanecarboxamide (PF-03654764).
Travis T. Wager,Betty Pettersen,Anne W. Schmidt,Douglas K. Spracklin,Scot Richard Mente,Butler Todd W,Howard Harry R,Daniel J. Lettiere,David M. Rubitski,Diane F. Wong,Frank M. Nedza,Frederick R. Nelson,Hans Rollema,Raggon Jeffrey W,Jiri Aubrecht,Jody Freeman,John M. Marcek,Julie Cianfrogna,Karen W. Cook,Larry C. James,Linda A. Chatman,Philip A. Iredale,Michael J. Banker,Michael Homiski,Jennifer B. Munzner,Rama Y. Chandrasekaran +25 more
TL;DR: Overall, clinical compounds 6 and 7 exceeded conservative safety margins and possessed optimal pharmacological and pharmacokinetic profiles, thus achieving the initial goal of identifying compounds with fully aligned oral drug attributes, "best-in-class" molecules.
93
Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor.
David Gray,John A. Allen,John A. Allen,Scot Richard Mente,Rebecca E. O’Connor,George J DeMarco,Ivan Viktorovich Efremov,Patrick L. Tierney,Dmitri Volfson,Jennifer Elizabeth Davoren,Edward Guilmette,Michelle A. Salafia,Rouba Kozak,Michael D. Ehlers,Michael D. Ehlers +14 more
TL;DR: A novel series of selective, potent non-catechol D1R agonists with promising in vivo pharmacokinetic properties are reported, and the molecular basis for catechol-specific recruitment of β-arrestin to D1Rs is defined.